The anti-PM/Scl autoantibody has been described in patients with scleromyositis. However, there are scant studies evaluating its prevalence and reactivity in dermatomyositis and polymyositis. METHOD: A cross-sectional, single center study evaluating the anti-PM/Scl autoantibody in 85 dermatomyositis and 32 polymyositis patients, without overlapping syndrome, was conducted between 2000 and 2016. Clinical data and complementary examinations were reviewed from electronic medical records with pre-parameterized information.
■ INTRODUCTION
Dermatomyositis (DM) and polymyositis (PM) are autoimmune systemic myopathies that primarily affect skeletal muscle. In the case of DM, there is also a cutaneous involvement, including the classic lesions known as heliotrope and Gottron's papules. 1, 2 Extramuscular manifestations may also occur, with joint, cardiac, pulmonary and/or gastrointestinal tract involvements. 2 The anti-PM/Scl antibody is considered to be associated with myositis and is typically described in patients with overlap syndrome, such as systemic sclerosis and autoimmune myositis. [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] This autoantibody has also been described in few cases of DM or PM without overlapping syndrome. 4, 5, 7, 8, [11] [12] [13] [14] [15] [16] [17] [18] [19] However, in this context, the autoantibody was correlated with the presence of interstitial lung disease, 11, 13, [17] [18] [19] neoplasia 7, 13, 16, 18, 19 or palmar and/or plantar hyperkeratosis.
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Anti-PM/Scl in isolated myositis Alves SP papule, facial rash, "V-neck" sign, "shawl" sign, periungual hyperemia, vasculitis, calcinosis, ulcers, Raynaud's phenomenon, palmar/digital hyperkeratosis ("mechanic hands") and plantar hyperkeratosis, muscle weakness of upper and lower limbs, dysphagia and pulmonary (dyspnea: moderate to low effort, rapid evolving dyspnea: less than 3 months after onset of general symptoms); 3. Changes on high-resolution computer tomography images of the lung: incipient pneumopathy, "ground glass" (opacity) and pulmonary fibrosis in both lung bases.
4. Serum levels of muscle enzymes in blood samples taken routinely for medical consultation: creatine phosphokinase (reference value: 32-294 U/L), and aldolase (1.0-7.5 U/L).
Recurrences of PM/DM were diagnosed on the basis of the following criteria: clinical relapse (i.e. muscle and/or dermatological manifestations); biochemical relapses (i.e. increase of serum muscle enzymes for which there was no other explanation).
A complete clinical response was considered after a 6-month continuous period of no evidence of disease activity while still receiving myositis therapy. Clinical remission was defined as the 6-month continuous period with no evidence of disease activity while not receiving any myositis therapy. Relapsing was defined as any renewed clinical and/or laboratory disease activity. 21 Serum samples stored at -20ºC were collected for the analysis of the autoantibodies at the time of the initial investigation of the active disease (laboratory and clinical). Identification of the anti-PM/Scl autoantibody, as well as of anti-syntheses (anti-Jo-1, PL-7, PL-12, OJ and EJ), anti-SRP, anti-Ku and anti-Mi-2 were performed using a commercial kit (Myositis Profile 3, Euroimmun, Germany) according to the manufacturer's protocol. The evaluation of the results was based on the methods established in a previous study. 22 In the case of the anti-MDA-5 autoantibody, identification was performed using the Enzyme-linked immunosorbent assay (ELISA) method, through recombinant MDA-5 and the anti-MDA-5 monoclonal antibody (MyBioSource, CA, USA). Results were evaluated according to methods established in a previous study. 23 Anti-HMGCR antibody was assayed by enzyme-linked immunosorbent assay (ELISA), using recombinant HMGCR protein and anti-HMGCR polyclonal antibody (MyBioSource, CA, USA). For the purposes of this study, patients with anti-HMGCR values greater than three standard deviations from the mean of 8 healthy individuals were considered positive. The rheumatoid factor was assayed by the nephelometry method.
Statistical 5, 7, 8, [11] [12] [13] [14] [15] [16] [17] [18] [19] (c) patients with lung diseases, 5, 7, 8, [11] [12] [13] [14] [15] [16] [17] [18] [19] (d) smokers (5, 7, 8, (11) (12) (13) (14) (15) (16) (17) (18) (19) , (e) neoplasias, 7, 13, 16, 18, 19 among others. Therefore, the primary objective of the present study was to evaluate the prevalence of the anti-PM/Scl autoantibody in a large number of patients with pure DM or PM, addressing previous study limitations. A secondary aim was to evaluate a possible association between this autoantibody and the clinical and laboratory evaluations as well as the complementary exam parameters of patients with DM and PM.
■ PATIENTS AND METHODS
A cross-sectional, single-center study evaluating the presence of the anti-PM/Scl autoantibody in adult patients with definite DM or PM (defined or probable) according to the criteria of Bohan and Peter 1 was conducted. All patients evaluated were seen at our tertiary service between 2000 and 2016.
This study was approved by the institutional Ethics Committee.
Exclusion criteria were the presence of associated systemic autoimmune diseases (overlap syndrome) -including systemic sclerosis (skin hardening (fibrosis), sclerodactilia, telangiectasias), neoplasia, pulmonary infections (turberculosis, aspergilloma) and chronic obstructive pulmonary disease, history of smoking, suspected cases of other myopathies (muscular dystrophies, metabolic myopathies and necrotizing immune-mediated myopathies), clinically amyopathic DM, and positivity for anti-Scl70, anti-centromere, rheumatoid factor, antisynthetase (anti-Jo-1, PL-7, PL-12, OJ or EJ), anti-MDA-5, anti-SRP or anti-HMGCR autoantibodies.
Of the initial 340 patients, 223 were excluded after applying the exclusion criteria. Thus, 117 consecutive patients were analyzed: 85 (72.7%) DM and 32 (27.3%) PM patients.
The following data on eligible patients were evaluated from electronic medical records, with pre-standardized and parameterized information. The following information on the initial diagnostic investigation in patients with clinicallaboratory activity was assessed:
1. Demographics: age at disease diagnosis, time between diagnosis and symptoms onset, gender and ethnicity.
2. Clinical manifestations: constitutional symptoms (fever and weight loss), heliotrope, Gottron's sign/
■ RESULTS
A total of 85 (72.7%) DM and 32 (27.3%) PM patients were included. Demographic, clinical, laboratory and complementary data are given in Table 1 .
Mean age of patients with DM and PM was 41.1 and 42.8 years, respectively, and both groups were predominantly Caucasian females (Table 1) . More than half of the patients had constitutional symptoms at disease onset. In addition, the majority of patients had Grade III or IV muscular strength in upper and lower limbs. Approximately one-third of the patients also had joint, gastrointestinal and pulmonary tract involvement.
Changes on computed tomography images of the chest were observed in both groups, with predominance of incipient pneumopathy, followed by "ground glass" lesions and pulmonary fibrosis.
The anti-PM/Scl autoantibody was observed in 5 out of 85 (5.9%) patients with DM, and 2 out of 32 (6.3%) with PM. In addition, 2 of these PM patients also had positivity for the anti-Ku autoantibody.
The overall characteristics of the 7 patients with anti-PM/Scl autoantibody are shown in Table 2 . Age ranged from 28 to 84 years, and individuals were predominantly female gender and caucasian. Follow-up time ranged from 3 to 17 years.
All 7 patients presented constitutional symptoms. Other relevant clinical manifestations were muscular (100%), pulmonary (85.7%) and joint involvement (71.4%), "mechanic hands" (85.7%), Raynaud's phenomenon (85.7%) and plantar hyperkeratosis (85.7%).
Laboratory creatine phosphokinase and aldolase levels ranged from 210 to 8065 U/L, and 10 to 163 U/L, respectively.
Regarding the evolution of these 7 patients, all had disease relapse during the follow-up period and used glucocorticoids and different immunosuppressant drugs. At the end of the present study, 5 patients showed complete clinical response and 2 complete remission of the disease.
■ DISCUSSION
Our study revealed a low frequency of the anti-PM/ Scl autoantibody in patients with DM and PM without overlap with other autoimmune diseases. In addition, these patients had a similar picture to that of antisynthetase syndrome, with relapses of disease activity.
The anti-PM/Scl antibodies were identified in 1977 by Wolfe et al. 24 These autoantibodies are directed against a nucleolar macromolecular complex of peptides of 75 kDa (PM/Scl-75 protein) and 100 kDa (PM/Scl-100 protein), with PM/Scl-75 considered the main autoantigen. 7 In the present study, care was taken to exclude patients with a diagnosis of possible PM and probable or possible DM, according to the criteria of Bohan and Peter, 1 as well as patients with other autoimmune systemic diseases, thus avoiding any possible selection bias.
Available studies 4, 5, 7, 8, [11] [12] [13] [14] [15] [16] [17] [18] [19] have evaluated the presence of the anti-PM/Scl autoantibody in patients with DM and PM, but failed to report possible confounders of pulmonary involvement, such as current or previous pulmonary infections, chronic obstructive pulmonary disease, or a history of smoking and/or the presence of an antisynthetase syndrome. However, in the present study, patients with any of these parameters were excluded.
Unlike previous studies 13, 19 our analysis included no patients with neoplasia, since this parameter was an exclusion criterion. The objective was to exclude any paraneoplastic conditions.
Reactivity to the anti-PM/Scl autoantibody as a function of disease activity (DM or PM) is unclear; therefore our analysis was based on blood samples collected at the time of the initial investigation of clinical and laboratory disease activity.
In contrast to the study by Muro et al, our 12 patients with clinically amyopathic DM presented, among various phenotypic features, a high prevalence of pulmonary involvement, especially in the presence of anti-MDA-5 autoantibody. [25] [26] [27] [28] After the application of strict inclusion and exclusion criteria, the prevalence of anti-PM/SCl in the present study was 5.9% and 6.3% in DM and PM patients, respectively.
We would also like to note that although previous studies had significant sampling limitations, the prevalence of the anti-PM/Scl autoantibody was observed in 7 -8% and 7.5 -7.9%, of DM and PM patients, respectively. 10, 14, 16 The lower prevalence of the anti-PM/Scl autoantibody in our series might have been due to the rigorous application of the inclusion and exclusion criteria.
A number of studies investigating several systemic autoimmune diseases or overlap syndromes have shown that the presence of the anti-PM/Scl autoantibody is associated with pulmonary conditions, 11, 15, [17] [18] [19] 25, [28] [29] [30] joint conditions, 5, 11, 15, 18, 30 Raynaud's phenomenon, 11, 15, 18, 30, 31 "mechanic hands" 17, 18, 25, [28] [29] [30] and/or plantar hyperkeratosis. 5, 7, 11, 13, [17] [18] [19] In this respect, the phenotypic manifestation of this autoantibody resembles that of antisynthetase syndrome. 15, 17, 18, 29, 30 In the present study, after application of the inclusion and exclusion criteria, the 5 DM and 2 PM patients with the anti-PM/Scl autoantibody also exhibited clinical symptoms similar to those of antisynthetase syndrome. All patients presented myositis, constitutional symptoms, including fever, at disease onset. Two of these 7 patients also had arthritis, Raynaud's phenomenon, "mechanic hands" and incipient pneumopathies.
It is important to note that previous studies have shown correlation of the anti-PM/Scl autoantibody with the presence of interstitial lung disease and plantar hyperkeratosis. 5, 7, 11, 13, [17] [18] [19] Cox et al. 31 showed that, out of 9 patients with plantar hyperkeratosis, 8 had "mechanic hands" and 7 anti-synthetase syndrome. Therefore, it is possible that this plantar manifestation has the same underlying basis as "mechanic hand". In fact, we observed the presence of both plantar hyperkeratosis and "mechanic hands" in 5 anti-PM/Scl positive patients with DM and one with PM.
Limitations of the study included the fact that no pulmonary function tests and no objective esophagus studies, both important exams, were performed.
■ CONCLUSIONS
There was a low frequency of the anti-PM/Scl autoantibody among DM and PM patients without overlap
